Trans Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-06-2024
- Paid Up Capital ₹ 5.00 M
as on 24-06-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 6.00 M
as on 24-06-2024
- Revenue -85.01%
(FY 2021)
- Profit 13.81%
(FY 2021)
- Ebitda 5.81%
(FY 2021)
- Net Worth -11.54%
(FY 2021)
- Total Assets -10.63%
(FY 2021)
About Trans Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹6.00 M.
Ganesh Chintawar, Satish Gadewar, and Sanjay Gugle serve as directors at the Company.
- CIN/LLPIN
U24112PN2010PTC136897
- Company No.
136897
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2010
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Ahmed Nagar, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Trans Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesh Chintawar  | Director | 21-Sep-2015 | Current |
| Satish Gadewar | Director | 21-Sep-2015 | Current |
| Sanjay Gugle | Director | 20-Jul-2010 | Current |
Financial Performance and Corporate Structure Insights of Trans Pharmaceuticals.
Trans Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 85.01% decrease. The company also saw a substantial improvement in profitability, with a 13.81% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trans Pharmaceuticals?
In 2021, Trans Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Ahmednagar Merchants' Co-Operative Bank Limited Creation Date: 12 Dec 2014 | ₹1.00 M | Open |
The Ahmednagar Merchant's Co-Op.Bank Ltd. Creation Date: 11 Feb 2011 | ₹5.00 M | Open |
How Many Employees Work at Trans Pharmaceuticals?
Trans Pharmaceuticals has a workforce of 8 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trans Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trans Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
